FEB 27, 2019 8:00 AM PST

Prepare for success: GMP cell banks as part of a staged, standardized, platform-style cell production process

  • CEO and Co-Founder of Pluristyx Inc.
      Ben Fryer is the CEO and co-founder of Pluristyx Inc. providing GMP pre-expanded pluripotent stem cells, contract development services, and consultancy for groups and company developing cell and tissue therapies. Ben has almost 25 years of experience as a leader and scientist in large pharma, academia, and start-up companies developing combination products and cell therapies. He has worked to generate GMP/ clinical grade pluripotent stem cells from early banking through large scale expansion using scalable, closed-loop, suspension reactor processes to manufacture cell therapy treatments for diabetes and heart disease.

      Ben is an inventor on multiple issued patents and patent applications for BetaLogics/Janssen/ J&J, including a bioreactor based, stem cell suspension expansion and differentiation process and a product currently marketed by Thermo-Fisher(TM) as Nunclon-Vita.

      Ben earned his BA from Colorado College, his PhD from UPENN, and studied as a post-doctoral fellow in the Howard Hughes Laboratory of M. Celeste Simon at the University of Pennsylvania investigating the role of Hypoxia Inducible Factor in cancer and stem cell development.

    DATE:  February 27, 2019
    TIME:  8:00am PST
    Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture replacement organs and cellular therapies. Many groups have shown therapeutic proof-of-concept of PSC-derived cells or tissues in relevant animal models, but PSCs are still more of a promise than a reality because of manufacturing challenges.  The task of manufacturing a sufficient number of cells under Good Manufacturing Practices (GMP) to enable clinical trials and eventual commercialization is a substantial hurdle. Furthermore, all allogeneic therapies, including those derived from PSCs, must meet strict regulatory requirements. One such requirement is the need for extensive, costly characterization and safety testing of the parental cell line and the subsequent master and working cell banks (MCB/WCB). The time and expense required to complete this testing necessitates the MCB be of sufficient quality and size to meet not only the requirements of a Phase 1 regulatory filing (IND), but also for the lifetime of the product through late stage trials and commercialization. This presentation will focus on the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and manufacturing workflow, beginning with the starting cell source and MCB.  Generation of a high-quality MCB is especially crucial for PSC-derived therapies because the first and most critically important step in product manufacturing is procurement of GMP-compliant starting material that meet regulatory requirements. Consequently, using high-quality raw materials from suppliers experienced in supporting cell therapy development and GMP manufacturing increase the probability of success and reduce the risk of costly surprises that could spell clinical or financial failure for a promising cell therapy product.  
    Learning Objectives:
    • Understand how and why cell banking is used for cell therapy manufacturing
    • Understand how and why to incorporate quality reagents and raw materials early in the development process
    Watch our related webinars here:
    LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

    Show Resources
    Show Resources
    • See more
    Connect with us